The INK4a/ARF locus which is frequently inactivated in human tumours encodes two dierent tumour suppressive proteins, p16 INK4a and ARF. p16
Introduction
The INK4a/ARF locus encodes two gene products, p16
INK4a and ARF, both of which are crucial for cell growth regulation and senescence (Quelle et al., 1995; Chin et al., 1998) . p16
INK4a is a major component of the RB pathway (Serrano et al., 1993) . ARF has been principally ascribed to exert a negative control on abnormal proliferative signals including ras , c-myc , E1A (De Stanchina et al., 1998) , Abl (Radfar et al., 1998) , and E2F1 by participating to a well de®ned ARF/mdm2/p53 pathway Pomerantz et al., 1998; Stott et al., 1998; Zhang et al., 1998) . Because ARF loss in mice facilitates spontaneous tumour development (Kamijo et al., 1997) , it has been proposed to be most important in tumour surveillance (Sherr, 1998) . ARF increases p53 activity by interacting with the mdm2 protein. Mdm2 is encoded by a p53-responsive gene and antagonizes p53 function by inhibiting its transcriptional activity, catalyzing its ubiquitination through its E3 ligase activity, and triggering its nuclear export and degradation in cytoplasmic proteasomes (for review see Levine, 1997; Prives, 1998) . ARF is able to sequester mdm2 in nucleoli and to inhibit its nuclear export (Weber et al., 1999; Tao and Levine, 1999) . This prevents the mdm2-mediated p53 degradation and thus stabilizes a transcriptionally active p53 in the nucleoplasm.
Some recent data have shown that ARF is not implicated only in this ARF/mdm2/p53 pathway. Carnero et al. (2000) reported that p19 ARF (murine ARF) is able to suppress colony formation in p53 7/7 cells by aecting the Rb pathway. Weber et al. (2000) provided evidence that reintroduction of p19 ARF in mouse embryo ®broblasts (MEFs) lacking p53, mdm2 and p19 ARF stops cell proliferation. In addition, mice lacking both p53 and ARF develop a more diverse spectrum of tumours than animals lacking either gene alone (Weber et al., 2000) . Altogether these observations demonstrated that the antiproliferative functions of ARF are not restricted to the p53 pathway. However, the relevant ARF target protein(s) implicated in this p53-independent pathway remains unknown.
E2F1, one of the upstream transcriptional activators of the ARF gene , is a major component of the RB pathway. It was the ®rst identi®ed member of a transcription factors family generically referred to as E2F (Nevins, 1992) . E2F1 plays a critical role in G1/S transition by coordinating early cell cycle events with the transcription of genes required for S phase entry (De Gregori et al., 1995) . Its activity is tightly regulated by RB. Binding with an hypophosphorylated form of RB sequesters E2F1 into inactive repressive complexes and inhibits its transcriptional capacity (Flemington et al., 1993) . The phosphorylation of RB by cyclinD-cdk4/6 complexes in late G1 allows the release of a free active form of E2F1 (Helin et al., 1993) . Accordingly, impairing the RB function leads to abnormal proliferation related to the deregulation of E2F1.
We previously observed that a signi®cant proportion of high grade neuroendocrine human lung tumours displayed inactivation of both p53 and ARF genes (GazzeÂ ri et al., 1998) . This led us to propose that ARF could play a role independently of p53. Indeed, we show here that ARF is able to arrest cell-growth of human cell lines in a p53 independent manner. More interestingly, we demonstrate that human ARF displays physical and functional interaction with E2F1 and that mdm2 is required for the modulation of E2F1 activity by ARF. Overall, these data clearly identify E2F1 as a new direct ARF target and provide for the ®rst time a candidate for the growth regulatory function of ARF at the interface of both p53 and RB pathways.
Results

Human ARF inhibits cell growth independently of p53
To test the hypothesis that ARF might display p53-independent functions we transfected an ARF expression vector in Saos2 (human osteosarcoma) and H358 (human bronchioloalveolar carcinoma) p53-null cell lines. After 2 weeks of drug selection, resistant cells were counted. As shown in Figure 1 , a high decrease in the number of cells was observed after ARF transfection in both cell lines when compared to cells transfected with an empty vector. Same results were obtained when the cells were transfected with a mutant ARF expression vector containing the exon 1b (referred to here as GST-ARF 1 ± 65 ). In contrast, the exon 2 of ARF (GST-ARF 66 ± 132 ) had no eect. Since we never detected apoptosis in ARF-transfected cells (data not shown), these data indicated that ARF was able to inhibit cell growth in the absence of wild-type p53.
Human ARF interacts with E2F1
E2F1, an upstream activator of ARF, is required for cell cycle progression (Helin, 1998) . In an eort to identify proteins that could be involved in the p53-independent growth arrest induced by ARF, we investigated a putative regulation of E2F1 by ARF. The E2F1 protein levels were analysed by direct immunoblot of crude extracts of Saos2 and H358 cells transfected with ARF. No dierence was observed in the steady state levels of the protein after overexpression of ARF (Figure 2a, left) . Nonetheless, the presence of complexes between ARF and E2F1 was detected by immunoprecipitation using antibodies to each protein ( Figure 2a , middle and right). Identical results were obtained from cells cotransfected with both ARF and E2F1 (Figure 2b) . In order to demonstrate that ARF/E2F1 complexes were not artefacts generated by overexpression of the proteins, immunoprecipitation experiments were repeated in 293 cells (human kidney cells transformed with Adenovirus 5 DNA) that contain relatively high levels of endogenous ARF. When ARF immunoprecipitates from 293 cells were immunoblotted with antibody against E2F1, co-precipitation of both proteins was detected again indicating that the interaction occurred also between the two endogenous proteins (Figure 2c ). ARF-E2F1 binding was further investigated in a cellfree system using a glutathione S-transferase (GST)-ARF fusion protein. In this direct binding assay, in vitro translated E2F1 co-precipitated eciently with the recombinant ARF protein demonstrating that both proteins had the ability to physically interact ( Figure  2d ). This result was con®rmed by examining extracts of sf9 cells infected with ARF and E2F1-baculovirus (data not shown). Taken together, these data indicate that ARF can form stable complexes in vivo with either endogenous or exogenous E2F1. In addition, the results of the in vitro assays strongly suggest that this association occurs even in the absence of other partners such as p53 and mdm2.
ARF inhibits the transcriptional activity of E2F1
E2F1 controls the expression of a number of genes needed for DNA synthesis and progression into S phase (De Gregori et al., 1995) . The ®nding of a direct interaction between human ARF and E2F1 prompted us to examine potential eect of ARF on E2F1-dependent transcription. In this respect, H358 cells were co-transfected with ARF and E2F1 expression vectors and a plasmid encoding the Chloramphenicolacetyl-transferase (Cat) reporter gene under the control of a promoter bearing E2F1 elements. Catassays repeatedly indicated that ARF signi®cantly inhibited E2F1 transactivating activity in a dose- dependent fashion (Figure 3a,b) . In contrast, the activity of an E2F1-independent reporter construct (PCAT3) was unaected by ARF overexpression ( Figure 3a ) and unrelated PCMV lacZ and PCMV luc control plasmids did not modulate the activity of the E2F1-dependent reporter construct ( Figure 3b ). Taken together these results indicated that downregulation of E2F1CAT by ARF was not the result of unspeci®c transcriptional inhibition. Furthermore, this inhibition was con®rmed in several cell types including normal cells (Figure 3c ).
Finally, we further investigated the ARF ability to inhibit endogenous E2F1 transcriptional activity in Saos2 cells that abundantly express E2F1. In these cells, we found that the activity of an E2F1-dependent reporter plasmid cyclinE-Luc but not of a control plasmid PGLuc was downregulated by ARF ( Figure  3d ). From these data we concluded that ARF had also the ability to inhibit endogenous E2F1 transcriptional activity. Since Saos2 cells lack functional RB, these data also indicate that ARF inhibition of E2F1 transcriptional function does not require the presence of RB. (speckled bars) expression vectors as described. The promoter activity of the E2F1-CAT reporter in the presence of E2F1 expression vector was normalized to 1 and the activity in the presence of ARF expression vectors was expressed relative to this CAT activity.
Results are the mean of three independent experiments performed in duplicate Oncogene ARF inhibits E2F1 activity B Eymin et al
Exon1b of ARF is necessary and sufficient to interact with E2F1 and to mediate inhibition of its transcriptional activity
We next looked for sequences implicated in the ARF/ E2F1 interaction and inhibition of E2F1 transcriptional activity. To this end we constructed a set of dierent ARF-GST fusion proteins and used them in a pull-down assay after incubation with in vitro translated E2F1. The study of E2F1 sequences implicated in ARF binding was performed using two truncated E2F1 proteins translated and radiolabelled in vitro: the ®rst one bore the 1 ± 374 N-terminal residues (E2F1 1 ± 374
) including sequences involved in DNA binding capacity of E2F1 and interaction with its cofactor DP-1; the second one contained the carboxy-terminal residues 323 ± 437 that encode E2F1 transactivation domain (E2F1 323 ± 437 ). A GST pulldown assay using a wild type ARF-GST fusion protein showed that E2F1 residues 1 ± 374 were implicated in ARF binding whereas the 323 ± 437 Cterminal sequence of E2F1 was not (Figure 4a ). These data indicate that E2F1 interacts with ARF through its N-terminal domain.
The same approach was repeated with in vitro translated wild type E2F1 and mutant GST-ARF fusion proteins. We found that the N-terminal domain of ARF (referred to here as GST-ARF 1 ± 65 ) was sucient to bind E2F1 (Figure 4b ) and to inhibit its transcriptional activity in a Cat assay (Figure 4c ). In contrast, the C-terminal part (GST-ARF 66 ± 132 ) did not react with E2F1 ( Figure 4b ) and was not able anymore to inhibit E2F1 transcriptional function (Figure 4c) . Strikingly, the HA-ARF 1 ± 65 protein exhibited a higher reducing transcription capacity than its wild type counterpart. The same results were obtained when these ARF mutants proteins were tested for their ability to inhibit the transcriptional activity of endogenous E2F1 using cyclinE-Luc reporter vector (data not shown).
The nucleolar accumulation of ARF has been reported to govern its activity towards its mdm2 and p53 eectors (Weber et al., 1999; Tao and Levine, 1999) . Two sequences necessary for nucleolar ARF localization have been identi®ed in exon1b (residues 1 ± 29) and exon2 (residues 83 ± 101) of human ARF (Weber et al., 1999; Zhang and Xiong, 1999; Rizos et al., 2000) . Implication of ARF nucleolar localization in the inhibition of E2F1 was tested using a myc-tagged ARF deletion mutant (referred to here as myc-ARF 1 ± 82 ) that lack the 50 C-terminal residues of exon2. As expected, myc-ARF 1 ± 82 diused throughout both the cytoplasm and the nucleus of the majority of transfected cells (data not shown and see also Zhang and Xiong, 1999) and was still able to interact with E2F1 (data not shown). In these conditions, inhibition of E2F1-dependent transcription was maintained (Figure 4c ). Taken together, these data demonstrate that exon1b of ARF is necessary and sucient to mediate E2F1 transcriptional inhibition but that nucleolar localization of ARF is not implicated in this process. 
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7/7 were co-transfected with either 1 mg PGLuc alone (hatched bars) or 1 mg cyclin E-luc (®lled bars) and 0.05 mg pCMV-E2F1, and various amounts (0.1 ± 0.5 mg) of pCDNA-ARF as indicated, in the absence (b) or presence (c) of 5 mg pCMV-mdm2 expression vector. Luciferase activity obtained with cyclin-E luc reporter in the presence of pCMV-E2F1 expression vector or with PGLuc alone was normalized to 1 and the activities of the remaining transfection reactions were expressed relative to this. (c) is representative of an experiment performed with 5 mg pCMV-mdm2. Other experiments with 0.25 mg pCMVmdm2 expression vector gave the same result
Inhibition of E2F1 transcriptional activity by ARF is dependent of mdm2
Mdm2 has been shown to contribute to ARF function through both the p53 and the RB pathways (Carnero et al., 2000) . Indeed, in H358 and Saos2 cells transfected with ARF, endogenous mdm2 was found to coprecipitate with ARF or E2F1 (data not shown) suggesting that it might play a role in ARF-mediated E2F1 activity. To get further insight into the potential implication of mdm2 in our system, we cotransfected mdm2
7/7 (double-null) mouse embryonic ®bro-blasts (MEFs) with ARF and E2F1 (since we did not detect endogenous E2F1 in these cells). Consistent with the data presented in Figure 2d , E2F1 coprecipitated with ARF in the absence of mdm2 (Figure 5a ). Nevertheless, in these conditions wild type ARF had lost its ability to inhibit the transcriptional activity of E2F1 (Figure 5b ). In contrast, after reintroduction of mdm2 product we partially restored ARF ability to inhibit E2F1 transcriptional function (Figure 5c ). Taken together, these results demonstrate that mdm2 is implicated in the modulation of E2F1 activity by ARF.
Discussion
Until recently, ARF was principally ascribed to be part of a three-partners ARF-mdm2-p53 pathway that exerts a negative control on abnormal proliferative signals. This eect was achieved through ARFmediated neutralization of mdm2 that resulted in the stabilization of a transcriptionally active p53 Pomerantz et al., 1998; Stott et al., 1998; Zhang et al., 1998) . However, recent data reported that murine ARF was able to arrest cell growth independently of p53 implying that p19 ARF may functionally interact with proteins other than p53 (Carnero et al., 2000; Weber et al., 2000) . Our present results provide evidence that human ARF is also able to arrest cell growth in human p53-null cell lines and identify E2F1 as a new target for ARF.
E2F1 has the ability to promote cell proliferation and/or apoptosis depending on the cellular context (Dyson, 1998) . In p53 expressing cells, E2F1 potentiates cell death probably through its capacity to transactivate ARF leaving p53 free for promoting apoptotic process . In contrast, in p53-null cells, E2F1-induced apoptosis does not require an intact E2F1 transactivation domain (Hsieh et al., 1997; Philipps et al., 1997) . Since our data show that ARF inhibits E2F1 transactivating activity, it is unlikely that ARF aects the E2F1 pro-apoptotic function. In contrast, ARF could modulate the ability of E2F1 to induce cell proliferation which is greatly dependent on its capacity to transactivate the expression of several genes implicated in G1/S transition (Dyson, 1998) . Consistent with this, p19 ARF has been recently reported to induce a G1 arrest in p53-null cells by preventing an unknown target to mediate G1 exit (Weber et al., 2000) . In addition, Carnero et al. (2000) demonstrated that strong expression of E2F1 was sucient to overcome the arrest induced by p19 ARF in p53 7/7 cells suggesting that p19 ARF might ultimately act by regulating E2F1. Our ®nding that ARF can interact with E2F1 and inhibit its transcriptional activity clearly identi®es E2F1 as an eector by which ARF can inhibit cell growth in a p53 independent context. In this respect, ARF can be viewed as a dual-regulatory component of both the p53 and RB pathways. Additionally, E2F1 can directly activate ARF transcription as well as its own expression (Johnson et al., 1994) . Thus, a direct ARF/E2F1 interaction could also allow ARF to negatively regulate its own expression as well as E2F1 expression. Consistent with this view, we recently observed that loss of ARF expression was frequently associated with elevated levels of E2F1 product (Eymin et al., 2001) . Overall, modulation of E2F1 transcriptional activity by ARF makes sense with the direct implication of ARF in oncogenic processes as inactivation of ARF would relieve a block in cell cycle progression by deregulating E2F1 activity.
We found that the inhibition of E2F1 transcription activity induced by ARF was lost in p53
MEFs. However, in our hands, reintroduction of mdm2 in these cells restored some repression of E2F1 transcriptional capacity. These data indicate that mdm2 protein is required for the ARF-induced inhibition of E2F1 transcriptional function to take place. In contrast, Weber et al. (2000) recently demonstrated that mdm2 antagonized ARF-mediated G1 arrest in MEF TKO (Triple knock-out for p53, ARF and mdm2). While we have no clear explanation for this discrepancy, Carnero et al. (2000) reported data also obtained in murine system, that demonstrated mdm2 cooperation in the activity of ARF in the p53 as well as in the RB pathways. As a whole, our results are more consistent with those of Carnero and indicate that direct interactions between ARF, mdm2 and E2F1 might constitute a pivotal structure in cell growth regulation processes. Mdm2 has been reported to stimulate the transactivatory capacity of E2F1 (Martin et al., 1995) . Paradoxically, we found that the inhibition of E2F1 transcriptional capacity induced by ARF was dependent on mdm2 expression. One hypothesis to this apparent discrepancy could be that binding of ARF to the mdm2-E2F1 complex would reverse the positive activity of mdm2 on E2F1 into inhibitory activity. As ARF 1 ± 65 residues have a signi®cant higher binding anity for mdm2 compared to wild type ARF (Rizos et al., 2000) , this could explain why this mutant ARF construct inhibits E2F1 transcription better than its wild type counterpart. In addition, these data would also be consistent with the ®nding that the exon2 C-terminal sequence of ARF which does not bind mdm2 (our data not shown and see also Midgley et al., 2000) does not inhibit E2F1 transcription.
Overall, our data identify E2F1 as a potential mediator of ARF functions independently of p53. An important consequence for human oncogenesis is that the so-called mutual exclusion resulting from the participation of p53 and ARF proteins to the same and unique pathway cannot be maintained anymore. In keeping with this situation, we and others have shown that in human lung tumours, coexistence of inactivated p53 and ARF proteins is not a rare event (GazzeÂ ri et al., 1998; Sanchez-Cespedes et al., 1999) suggesting that a growth advantage is gained by ARF invalidation in p53 mutant clones.
Materials and methods
Transfection and growth suppression assay
Transient transfections were carried out using FugeÁ ne 6 (Roche Diagnostic) according to the manufacturer's protocol. The total amount of DNA used for transfection was held constant by adding empty vector DNA to the transfection mixture. Cells were harvested 48 ± 72 h after transfection. In the growth suppression assay, G418 was added to the media 48 h post transfection and cells were maintained for 12 days to generate stable transfectants. Trypan blue excluding cells were counted.
Western blot analysis
Western blots were performed by using standard procedures with antibodies directed against ARF (Della Valle et al., 1997), E2F-1 (Ab-4, Neomarkers), myc (Ab-2, Neomarkers) or Haemagglutinin (HA) (3F10, Roche Diagnostic).
Immunoprecipitations
Mammalian cell pellets were lysed with 120 mM NaCl, 50 mM Tris pH 7.4, 0.5% NP40, 1 mM EDTA and incubated for 30 min on ice. The supernatants were cleared by centrifugation. Equal amounts of protein (200 mg) were precleared using protein A/protein G agarose beads and immunoprecipitated by using standard procedures. Antibodies used were anti-ARF (Della Valle et al., 1997) for ARF, KH95 (Pharmingen) for E2F1, myc Ab-1 (Neomarkers) for myc-ARF 1 ± 82 and clone 3F10 (Roche Diagnostic) for HA Tag.
GST pull-down assay
Beads coated with GST, GST-ARF, GST-ARF 1 ± 65 or GST-ARF 66 ± 132 fusion proteins were prepared according to the manufacturer's protocol (Bulk GST Puri®cation module, Pharmacia Biotech). Beads were incubated for 45 min at room temperature with equivalent amounts of in vitro translated 35 S-methionine-labelled E2F1 proteins (E2F1 1 ± 437; E2F1 1 ± 374; E2F1 323 ± 437; TNT SP6/T7 system, Promega) in a ®nal volume of 150 ml binding buer (25 mM HEPES pH 7.6, 12.5 mM MgCl 2 , 150 mM KCl, 0.1% NP40, 20% glycerol) containing 0.2 mg/ml BSA. Beads were washed three times with NETN buer (100 mM NaCl 1 mM EDTA, 0.5% NP40, 20 mM Tris pH 8.0), once with PBS and then analysed by 10% SDS ± PAGE.
Cat and luciferase assays
Two610
5 cells were transfected in a 6 cm dish. In CAT assays, transcriptional activity of E2F1 was analysed by measuring CAT activity using CAT ELISA (Roche Diagnostic). For Luciferase assays, cells were lysed at 24 h after transfection in 300 ml lysis buer (Passive lysis buer from Promega). The cell debris were removed by centrifugation at 14 000 r.p.m. for 2 min and luciferase activity was measured on a 20 ml aliquot in a luminometer using the luciferase kit from Promega.
